Current Report Filing (8-k)
May 25 2016 - 8:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
May
25, 2016
|
Date of report (Date of earliest event reported)
|
SurModics, Inc.
|
(Exact Name of Registrant as Specified in its Charter)
|
Minnesota
|
|
0-23837
|
|
41-1356149
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification
No.)
|
9924 West 74
th
Street
Eden Prairie, Minnesota
|
|
55344
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(952) 500-7000
|
(Registrant’s Telephone Number, Including Area Code)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(see General Instruction A.2):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On May 25, 2016, Creagh Medical Limited, a wholly-owned subsidiary of
SurModics, Inc. (the “Company”), entered into an agreement with Gerry
Barrett, Brian Conneely, and Noel Dillon to purchase the manufacturing
facility and related leasehold interests in the property located in
Ballinasloe, County Galway, Ireland (the “
Agreement
”). The
purchase price was €2,555,000, or approximately $2,871,000. The
agreement incorporates by reference the Incorporated Law Society of
Ireland General Conditions of Sale (2009 Edition) and contains other
customary terms and conditions.
The foregoing description of the Agreement does not purport to be
complete and is qualified in its entirety by reference to the full text
of Agreement. A copy of the Agreement will be filed as an exhibit to the
Company’s Quarterly Report on Form 10-Q for the quarter ended June 30,
2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SURMODICS, INC.
|
|
|
|
|
|
|
Date:
|
May 25, 2016
|
/s/ Bryan K. Phillips
|
|
|
Bryan K. Phillips
|
|
|
Sr. Vice President, General Counsel and Secretary
|
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2023 to Apr 2024